WHO ICTRP trial
Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19
IRCT20081027001411N4 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20081027001411N4 |
|---|---|
| Public title | Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 |
| Scientific title | Study of Tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ?crinical trial study |
| Primary sponsor | Tehran University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2 |
| Countries | Iran (Islamic Republic of);Iran (Islamic Republic of) |
| Conditions | COVID-19 disease. COVID-19, virus not identified;U07.2 |
| Interventions | Intervention 1: Intervention group: Patients hospitalized with COVID-19 disease will receive 8mg/kg Tocilizumab (Roche) in addition to their standard treatment. If the patients condition is not stable 2 doses by 12 hours will be… |
| Registration date | Jul 9, 2020 |
| Target size | 40 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: